157 related articles for article (PubMed ID: 26732854)
1. The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
Paximadis P; Najy AJ; Snyder M; Kim HR
Prostate; 2016 May; 76(6):534-42. PubMed ID: 26732854
[TBL] [Abstract][Full Text] [Related]
2. A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.
Christensen M; Najy AJ; Snyder M; Movilla LS; Kim HR
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):151-8. PubMed ID: 24331662
[TBL] [Abstract][Full Text] [Related]
3. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
5. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
6. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
7. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
11. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
12. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
[TBL] [Abstract][Full Text] [Related]
15.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
17. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
18. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
19. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
Dahl HC; Kanchwala M; Thomas-Jardin SE; Sandhu A; Kanumuri P; Nawas AF; Xing C; Lin C; Frigo DE; Delk NA
PLoS One; 2020; 15(12):e0242970. PubMed ID: 33326447
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]